Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET

NCT00668148 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00668148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00668148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2008
Completion date
February 29, 2012
Enrollment
113 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

adipocytic sarcoma, ewing's sarcoma /peripheral neuroectodermal tumor (pnet), leiomyosarcoma, rhabdomyosarcoma, synovial sarcoma